Activity of ceftolozane/tazobactam against surveillance and ‘problem’ Enterobacteriaceae, Pseudomonas aeruginosa and non-fermenters from the British Isles

Association of Novel Nonsynonymous Single Nucleotide Polymorphisms inampDwith Cephalosporin Resistance and Phylogenetic Variations inampC,ampR,ompF, andompCin Enterobacter cloacae Isolates That Are Highly Resistant to Carbapenems

(2016) Baharak Babouee Flury et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Salvage Therapy with Ceftolozane-Tazobactam for Multidrug-Resistant Pseudomonas aeruginosa Infections

(2016) Juan José Castón et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Successful treatment of multidrug-resistant Pseudomonas aeruginosa breakthrough bacteremia with ceftolozane/tazobactam

(2016) Alberto Hernández-Tejedor et al.   INFECTION

New β-Lactamase Inhibitors in the Clinic

(2016) Krisztina M. Papp-Wallace et al.   INFECTIOUS DISEASE CLINICS OF NORTH AMERICA

Successful Use of Ceftolozane-Tazobactam to Treat a Pulmonary Exacerbation of Cystic Fibrosis Caused by Multidrug-ResistantPseudomonas aeruginosa

(2016) Stephen B. Vickery et al.   PHARMACOTHERAPY

Ceftolozane/Tazobactam

(2015) Allana J. Sucher et al.   ANNALS OF PHARMACOTHERAPY

Mutations in β-Lactamase AmpC Increase Resistance of Pseudomonas aeruginosa Isolates to Antipseudomonal Cephalosporins

(2015) M. Berrazeg et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Ceftolozane/Tazobactam Therapy of Respiratory Infections due to Multidrug-ResistantPseudomonas aeruginosa: Table 1.

(2015) Michael S. Gelfand et al.   CLINICAL INFECTIOUS DISEASES

Update on infections caused by Stenotrophomonas maltophilia with particular attention to resistance mechanisms and therapeutic options

(2015) Ya-Ting Chang et al.   Frontiers in Microbiology

Pseudomonas aeruginosa Ceftolozane-Tazobactam Resistance Development Requires Multiple Mutations Leading to Overexpression and Structural Modification of AmpC

(2014) Gabriel Cabot et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Spread of extensively resistant VIM-2-positive ST235 Pseudomonas aeruginosa in Belarus, Kazakhstan, and Russia: a longitudinal epidemiological and clinical study

(2013) Mikhail V Edelstein et al.   LANCET INFECTIOUS DISEASES

Extended-spectrum and metallo-beta-lactamases among ceftazidime-resistantPseudomonas aeruginosain Riyadh, Saudi Arabia

(2012) Mohamed H Al-Agamy et al.   JOURNAL OF CHEMOTHERAPY

Overexpression of AmpC and Efflux Pumps in Pseudomonas aeruginosa Isolates from Bloodstream Infections: Prevalence and Impact on Resistance in a Spanish Multicenter Study

(2011) Gabriel Cabot et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Chequerboard titration of cephalosporin CXA-101 (FR264205) and tazobactam versus  -lactamase-producing Enterobacteriaceae

(2010) D. M. Livermore et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Inhibitor Resistance in the KPC-2  -Lactamase, a Preeminent Property of This Class A  -Lactamase

(2009) K. M. Papp-Wallace et al.   ANTIMICROBIAL AGENTS AND CHEMOTHERAPY

Activity of cephalosporin CXA-101 (FR264205) against Pseudomonas aeruginosa and Burkholderia cepacia group strains and isolates

(2009) David M. Livermore et al.   INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS

Molecular mechanisms disrupting porin expression in ertapenem-resistant Klebsiella and Enterobacter spp. clinical isolates from the UK

(2009) M. Doumith et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY

Survey, laboratory and statistical methods for the BSAC Resistance Surveillance Programmes

(2008) R. Reynolds et al.   JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY